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Aim. To establish anti-influenza activities for 8 compounds of adamantyl (alkyl, cycloalkyl) 
derivatives of aminopropanol-2 in vitro and in vivo investigations. Methods. The antiviral ac-
tion of compounds was determined in vitro by reduction of infectious titer of the influenza virus 
in the Madin-Darby Canine Kidney (MDCK) cell culture and in vivo on the model of influ-
enza pneumonia in mice. Results. Three of eight studied compounds inhibit the reproduction 
of the influenza virus strain A/FM/1/47(H1N1) by more than 2 lg ID50 in the concentration 
range from < 0.39 µg/ml (the compounds 30 and 33) to 1.56 µg/ml (the compound 5), their 
chemotherapeutic indices are 256 and 16, respectively. The experiments in vivo showed that in 
prophylactic scheme the efficiency index (EI) of the compounds 5 and 30 is 60 %; in therapeu-
tic scheme EI of the compounds 5 and 33 is 100 % that is two times higher, than for rimantadine. 
Conclusions. High chemotherapeutic indices of the compounds 30, 33 and their ability to sup-
press the influenza virus reproduction in the MDCK cell culture by more than 2 lg ID50 indicate 
the anti-influenza activity of these compounds. It has been also confirmed by in vivo experiment.
K e y w o r d s: influenza virus, adamantyl (alkyl, cycloalkyl) derivatives of aminopropanol-2, 
antiviral activity.
Introduction
For today in the world and in Ukraine in par-
ticular, is unstable epidemic situation for many 
infectious diseases, including viral. According 
to the WHO estimates by 2030, infection dis-
eases will be one of the major causes of mortal-
ity among people (Antimicrobial resistance: 
global report on surveillance 2014, http://apps.
who.int/iris/bitstream/10665/112642/1/97892 
41564748_eng.pdf?ua=1). Influenza is a lea der 
among the respiratory tract infections by the 
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number of cases and distribution. Airborne 
droplets way of distribution of flu infection 
leads to the rapid spread of the pathogen, and 
high antigenic variability of the influenza virus 
results in the appearance of new strains causing 
epidemics and pandemics. According to the 
WHO data, the flu and flu-like illnesses affect 
annually 5 – 30 % of the world population. The 
flu and acute respiratory viral infections annu-
ally affect about 15 million people in Ukraine 
[1]. Despite the recent achievements in diag-
nostics and therapy, the problem of treatment 
of influenza remains a relevant problem, as well 
as the establishment of effective chemothera-
peutic agents for prevention and therapy of this 
infection. Nowadays the process of creating 
new medicines commonly starts from finding 
new drug candidates – structural prototypes of 
future chemotherapeutic agents with the desired 
pharmacological effect [2]. The search for an-
timicrobial compounds is carried out among 
new chemical classes as well as among new 
derivatives of already known compounds af-
fecting certain targets. Since discovery of ada-
mantane its derivatives have proven to be the 
most promising as viral inhibitors [3–6]. The 
best of them is aminoadamantane (amantadine, 
rimantadine) [3, 7], which entered the pharma-
ceutical market and is successfully used as an 
anti-influenza drug.
The adamantane molecule is highly reactive 
compared with other hydrocarbons, which al-
lows obtaining a wide range of poly-function-
al derivatives. The molecule can be modified 
by the C–H bond activation for the direct nu-
cleophilic substitution or radical reactions 
[8–12]. It can be also modified by the introduc-
tion of substituents or heterocyclic atoms for 
designing new derivatives [13, 14]. 
It is known from literature that amino alco-
hols and the products of their substitution in 
the amino and hydroxyl groups have polyvalent 
pharmacological effects (stimulators or block-
ers of α and β-adrenaline, adrenaline mimetics, 
antibiotics, etc.) [15, 16]. It is also known that 
adamantane containing amino alcohols dem-
onstrates antiviral action [17]. The modification 
of β-adrena blockers structures via the introduc-
tion of various adamantyl fragments as amino 
groups results in the appearance of antivirus 
effects [18]. Based on this knowledge it seemed 
advisable to study an antiviral effect of new 
adamantane derivatives containing amino al-
cohols and their related alkyl and cycloalkyl 
structural analogs [19, 20].
Materials and Methods
The synthesized compounds
Investigated adamantanyl (alkyl, cycloalkyl) 
derivatives of aminopropanol-2 were synthe-
sized in Institute of Organic Chemistry of the 
NAS of Ukraine according to the procedures 
developed in [15]. The structure and purity of 
the synthesized compounds were proved via 
elemental analysis, proton magnetic resonance 
spectroscopy and chromatography mass spec-
trometry methods. The common formula of the 
tested compounds is 
ROCH2CH(OH)CH2R1
where: R – Ad(CH2)2, R1 – cyclohexylamin 
(the compound 5); R – Ad(CH2)2, R1 – 1,1,3,3- 
tetramethylbutylamine (the compound 6); R – 
tretbutyl, R1 – 2,2,6,6-tetraethyl piperidin 
amine (the compound 33); R – allyl, R1 – 
1,1,3,3-tetramethylbutyl-amine (the compound 
40); R – tret-amyl, R1 – 2,2,6,6-tetramethyl-
4-hydroxy piperidine amine (the compound 
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47); R – cyclopentyl, R1 – 2,2,6,6-tetramethyl-
4-hydroxy piperidine amine (the compound 
48); R – bornyl, R1 – 2,2,6,6-tetramethyl-4-hy-
droxy piperidine amine (the compound 51). 
The compounds 48 and 51 were investigated 
in the alkali form.
Depending on the radicals structure all test-
ed compounds were divided into the adaman-
tane containing (compounds 5 and 6), bornyl 
containing (the compound 51), the compounds 
with cyclic substituents in alkoxy group (the 
compounds 30 and 48) and the compounds 
with alicyclic substituents in alkoxy group (the 
compounds 33, 40, 47). All synthesized com-
pounds are colorless and odorless crystalline 
substances with different solubility in water 
and 96 % alcohol. The 1 mg/ml matrix solu-
tions of the studied compounds were prepared 
using a medium for cell cultures without se-
rum. These solutions were sterilized via filtra-
tion through cellulose filter with 0.22 µm pore 
diameter. The solution was stored in sterile 
bottles at –20 °C before using.
Virus and cell culture
The mouse-adapted influenza virus A/
FM/1/47(H1N1) was cultivated in Madin-
Darby Canine Kidney (MDCK) cells (ATCC, 
CCL-34). MDCK cells were cultured in 
Dulbecco’s modified Eagle’s medium 
(DMEM), supplemented with 5 % heat inac-
tivated fetal bovine serum (FBS) in 37 °C 
incubator with 5 % CO2. The influenza A/
FM/1/47(H1N1) and MDCK cells were ob-
tained from the Bank of cell cultures of the 
laboratory of experimental chemotherapy of 
viral infections of the L. V. Gromashevsky 
Institute of epidemiology and infectious dis-
eases of NAMS of Ukraine. 
Virological tests in vitro
Anti-influenza activity of the tested compounds 
was evaluated by chemotherapeutic index 
(CTI) determined as the ratio of the maximum 
tolerated dose (MTD) to the minimum active 
concentration (MAC). 
MTD was determined as the greatest con-
centration of the tested compound that did not 
cause the cytopathic effect (CPE) in the mono-
layer of MDCK cells [16, 17]. For this pur-
pose, the growing MDCK cells were plated at 
a density of 1 × 105 cells/ml and incubated in 
96-well plates for 24 h (37 °C, 5 % CO2). Then 
the cells were treated with the tested com-
pounds of different concentration (3.12, 6.25, 
12.5, 25, 50, 100 μg/ml) for 5 days. The wells 
containing no compounds were used as a neg-
ative control. In the experiments, we used at 
least ten holes for each dilution of the sub-
stance. The CPE was determined by changed 
cell morphology (degeneration or exfoliation 
of cells from the hole surface). 
MAC of the studied compounds was deter-
mined by the degree of reduction of infectious 
titer of the virus according to the General es-
tablished procedure [16, 17]. The virus titers 
were calculated as 50 % of tissue culture infec-
tious dose (TCID50) using the Kerber formula 
(Manual for the virological investigation of 
polio, http://apps. who.int/iris/bitstream/10665/ 
68762/1/WHO_IVB_04.10.pdf): 
Lg TCID50= L-d(S-0.5), 
where L – the initial dilution, d – the difference 
between Lg of serial dilutions, S – the sum of 
the proportions of tested objects, which gave 
a positive result.
The hemagglutination inhibition test (HAI) 
was carried out to study the influence of tested 
compounds on the influenza virus hemagglu-
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tination activity (HA). The tested substances 
diluted in the range of 50 – 0.36 mkg/ml were 
incubated with the virus (4 agglutination units) 
for 30 min at room temperature; 0.75 % eryth-
rocytes suspension of Guinea pigs were added, 
shaken and left at room temperature for 
60 min. As a titer of HAI was taken a limiting 
dilution, which gives a complete delay of the 
hemagglutination reaction, that is ++++.
Virological studies in vivo
The anti-influenza activity of tested compounds 
was studied via simulation of influenza pneu-
monia in mice using prophylactic and therapeu-
tic schemes of the compound introduction. In 
these studies, we used white outbred mice 
weighing 18–22 g, which were on the standard 
diet for at least 7 days. All experiments were 
performed with ten mice per group. 
For the prophylactic scheme the mice were 
intranasally (i.n.) inoculated with 0.2 ml of the 
tested compounds at 10×ID50 (50 %-mouse in-
fectious dose; sub-lethal) 24 h before infection 
with the influenza virus. For the therapeutic 
scheme this procedure was carried out 24 h after 
infection of mice with the influenza virus. At the 
same time for both schemes, the control was a 
group of animals infected with the influenza 
virus without administration of the tested com-
pounds. The influenza virus strain A/
FM/1/47(H1N1) with infectious titer in the 
MDCK cell culture 4.5 lg ID50, caused 100 % 
mortality of control group mice within 5 days. 
Observation of experimental animals was carried 
out for 7 days. It was also studied the effect of 
reference drugs in different regimens of admin-
istration to mice with experimental influenza 
pneumonia. As the reference drugs we used the 
known flu drugs Tamiflu® of pharmaceutical 
company F. Hoffman-La Roche, Switzerland (75 
mg per capsule) and Rimantadine of pharma-
ceutical company “Darnitsa”, Ukraine (50 mg 
tablets), which were administered at a dose of 
10 mg/kg of animal weight. 
The efficiency of protective action of the 
compounds was evaluated by the efficiency 
index (EI) of inhibition of lethality. EI of the 
tested substances was determined according to 
the formula [21]: 
EI = 
PC – 1
×100 %,
PC
where PC — protection coefficient defined as 
the ratio of the number of animals at the begin-
ning to that at the end of experiment.
Results and Discussion
The anti-influenza activity of new synthesized 
adamantyl (alkyl, cycloalkyl) derivatives of 
aminopropanol-2 was studied against the in-
fluenza virus strain A/FM/1/47(H1N1). The 
antiviral activity of tested compounds 5, 6, 30, 
33, 40, 47, 48, 51 was evaluated in vitro ex-
periments by their chemotherapeutic index 
(CTI) determined as the ratio of the maximum 
tolerated dose (MTD) to the minimum active 
concentration (MAC). MTD of the tested com-
pounds was determined by their cytotoxic ef-
fect on a monolayer of the MDCK cells cul-
ture. For this purpose, after 24-h cell growth 
the nutrient medium was replaced with the 
medium containing the tested compound in the 
concentration from 3.12 µg/ml to 100 µg/ml. 
In the control, no replacement was carried out. 
For the experiments at least ten wells with the 
cell culture were taken for each dilution of the 
compound. The level of CPE was determined 
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by the change in cell morphology (degenera-
tion or exfoliation of cells from the hole sur-
face). MTD of the tested compound was taken 
as its highest concentration that did not cause 
degeneration of cells in all ten wells. The re-
sults of MTD determination for the studied 
compounds are presented in figure 1.
The MAC index of the tested substances 
was determined in vitro in a monolayer of the 
MDCK cells cultures by the level of reduction 
of infectious titer of the virus, in accordance 
with the General established procedure [16]. 
With this purpose the test-virus in a dose of 
100 ID50 in 0.1 ml was introduced into the 
MDCK cells culture and incubated for 1 h at 
37 °C. Next, the virus was removed by wash-
ing with medium RPMI-1640, and the support 
medium (RPMI-1640 + 2% fetal serum) with 
the tested compounds in concentration from 
0.39 mcg/ml to 50 µg/ml was added. A reduc-
tion of infectious titer in the cell cultures trea-
ted with different concentrations of the tested 
compounds not less than 2 lg ID50 in the ex-
periment compared with control allowed us to 
establish MAC of the tested compounds for 
the influenza virus (see figure 2).
According to the data in fig. 2 the com-
pounds 47 and 48 have no influence on the 
reproduction of influenza virus in the studied 
concentrations (0.36 µg/ml to 50 µg/ml), they 
inhibit the development of virus-specific CPE 
in concentrations less than 2.0 lg ID50. The 
compounds 5, 6, 30, 33, 40, 51 inhibited the 
influenza virus reproduction more than 2.0 
lg ID50 in concentrations from of 1.56 µg/ml 
(compound 5) to 6.25 µg/ml (the compound 
40), which gives grounds to consider them to 
possess the antiviral activity. The compounds 
30 and 33 were the most active against the 
influenza virus, their MAC was the smallest 
and amounted to < 0.39 µg/ml. 
 
Fig. 2. The MAC of test 
compounds for influenza 
virus.
Fig. 1. The MTD of test compounds adamantyl (alkyl, 
cycloalkyl) of aminopropanol-2 derivatives
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MTD of anti- influenza drugs Rimantadine 
and Tamiflu was determined by CPE on the 
monolayer of the MDCK cell culture, and the 
value of their MAC was established by the 
degree of reduction of infectious titer of the 
influenza virus (Table 1). The data in the tab-
le 1 show that Rimantadine and Tamiflu were 
non-toxic to the MDCK cell cultures in a dose 
of 62.0 µg/ml and 250.0 µg/ml respectively, 
that corresponds to the value of MTD of these 
anti-influenza drugs.
The value of ratio of MTD to MAC of the 
studied compounds, and that of anti-influenza 
drugs Tamiflu and Rimantadine allowed us to 
determine their CTI. These data are shown in 
table 2.
Table 1. The value of CPE and MAC of anti-influenza drugs in relation to the influenza virus
Concentration of drugs µg/ml
anti-influenza drugs
Rimantadine  Tamiflu
 CPE Infectious titer of influenza virus (lg ID50)
 CPE Infectious titer of influenza virus (lg ID50)
500.0 0 NT 0 NT
250.0 0 NT 100 < 1.0
125.0 0 NT 100 < 1.0
62.0 100 4.0 100 < 1.0
31.0 100 4.0 100 < 1.0
15.5 100 4.0 100 < 1.0
7.75 100 4.0 100 4.0
Control of virus 100 4.0 100 4.0
* NT – not tested
Table 2. MTD, МАC and CТІ of the tested 
compounds, anti-influenza drugs Tamiflu and 
Rimantadine
compounds MTD,  mcg/ml
МАC,  
mcg/ml CТІ
5 25.0 1.56 16
6 12.5 3.125 4
30 > 50.0 0.36 256
33 > 50.0 0.36 256
40 > 50.0 6.25 8
47 12.5 0 –
48 < 100 0 –
51 12.5 3.125 4
Rimantadine  6200 0.36 172.2
Tamiflu 25 000 0.02 12 500
Table 3. The titer of HAI for compounds 5, 30, 33
Concentration 
of compounds 
μg/ml
The titer of HAI* tested compounds 
5 30 33
50.0 – – –
25.0 – ++++(1/512) –
12.5 – ++++(1/1024) –
6.25 – ++++(1/1024) –
3.1 – ++++(1/1024) –
1.55 – ++++(1/1024) –
0.72 ++++(1/512) ++++(1/1024) –
0.36 ++++(1/1024) ++++(1/1024) –
Control of 
virus ++++(1/1024) ++++(1/1024) ++++(1/512)
HAI * «-» – absence of hemagglutination ; «++++» – 
presence of hemagglutination,titer of HAI
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The values of MTD, МАC and CТІ of the 
compounds 30 and 33 correspond to the sub-
stances highly active against the influenza virus. 
CTI of these compounds was equal to 256 and 
was higher than the same index of the anti-in-
fluenza drug Rimantadine, CTI of which was 
172.2. The compound 5 is active against the 
influenza virus, its CTI equal to 16. The value 
of CTI of the compounds 6, 40 and 51 was also 
more than 3 (4, 8 and 4 respectively) (Table 2).
It is known that cells are sensitive to the 
influenza virus, bearing on their surface the 
receptors to viral glycoprotein of hemaggluti-
nin (HA). The braking hemagglutination activ-
ity of the viruses in some cases is associated 
with a loss of the virus infectivity; therefore, 
it is appropriate to evaluate the influence of 
compounds on the hemagglutinin properties 
of viruses. We examined the influence of the 
most active compounds 5, 30 and 33 on the 
hemagglutinate activity of the influenza virus 
using hemagglutination inhibition test (HAI) 
(Table 3). 
The titer of hemagglutination inhibition was 
the approved limiting dilution, which gives a 
complete delay of the hemagglutination reac-
tion. The results of determination of the effect 
of various concentrations of the tested com-
pounds on hemaglutinin properties of the in-
fluenza virus are shown in table 3. The data in 
the table 3 show that the compounds 30 and 
33 with the same value of MAC (< 0.39 µg/
ml) make different effects on the hemaglutina-
tion properties of the influenza virus. The com-
pound 33 influences the virus hemagglutinin 
in much smaller concentrations than the com-
pound 30. The HAI titers for the compound № 
33 is 0,36 µg/ml and the HAI titer for com-
pound № 30 is only 50 µg/ml. 
The anti-influenza activity of the tested 
compounds 5, 30 and 33 was determined in 
the in vivo experiments on the model of mice 
Table 4. Anti-influenza action of the compounds 5, 30, 33 and the anti-influenza drugs in vivo experiment.
Substances Concentration of substances mcg/ml
The number of mice Protection 
coefficient 
Efficiency index 
(EI), %the total number of them died, (%)
prophylactic scheme
5 1.55 10 4 (40 %) 2.5 60
30 0.36 10 4 (40 %) 2.5 60
33 0.36 10 8 (80 %) 1.25 20
Rimantadine 0.5 10 5 (50 %) 2 50
Tamiflu 0.02 10 2 (20 %) 5 80
therapeutic scheme
5 1.55 10 0 > 10 100
30 0.36 10 4 (40 %) 2.5 60
33 0.36 10 0 > 10 100
Rimantadine 0.5 10 6 (60 %) 1,66 39.7
Tamiflu 0.02 10 2 (20 %) 5 80
Control of virus 0 10 10 (100 %) – –
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influenza pneumonia. The efficiency of the 
protective action of the tested compounds and 
anti-influenza drugs in the prophylactic and 
therapeutic schemes of their administration is 
shown in table 4.
Among the studied substances only the 
compounds 5 and 30 protect mice from the 
lethal influenza infection in vivo experiments 
in the prophylactic scheme of administration 
(Table 6). Their efficiency indices are equal 
(60 %) and higher than the Remantadine EI by 
10 %. Unlike the substances 5 and 30 the 
compound 33 did not provide a significant 
protective effect in the prophylactic scheme of 
administration. EI of the compound 33 was 
only 20 %, which is much less than that of 
Tamiflu (80 %). The compounds 5 and 33 
showed a much greater protective effect in the 
therapeutic scheme of administration than in 
the prophylactic scheme of in vivo experiment. 
EI of these compounds was 100 % in the ther-
apeutic scheme of administration, compared 
to the prophylactic scheme, where their EI 
values were 60 % and 20 % respectively. 
Comparison of the protective effects of newly 
synthesized compounds 5, 30, 33 and anti-
influenza drugs Rimantadine and Tamiflu on 
the model of influenza pneumonia of mice in 
the prophylactic and therapeutic schemes of 
their administration is shown in figure 3.
The EI values of tested compounds 5, 30, 
and 33 were significantly different for different 
schemes of the in vivo experiment (Fig. 3). The 
tested compounds were more effective in ther-
apeutic scheme of their introduction, when 
influenza drugs showed the same effect in both 
variants of the experiment. Complete protec-
tion against experimental influenza infection 
in mice was observed for compounds 5 and 33 
in therapeutic scheme of their introduction. 
Their EI values were 100 %, that is more than 
twice higher than Rimantadine EI. The com-
pound 30 showed identical efficiency in dif-
ferent schemes of the in vivo experiment, its 
Fig. 3. Anti-influenza 
activity of the compounds 
5, 30, 33 and anti-influen-
za drugs Rimantadine and 
Tamiflu on the model of 
influenza pneumonia of 
mice in the prophylactic 
(1) and therapeutic (2) 
schemes of their adminis-
tration. 
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EI in both cases was 60 %. Noteworthy, for 
the compounds 30 and 33 an equally high CTI 
(256) was identified in vitro experiment, but 
these substances showed a different level of 
protective effect in vivo experiment.
Conclusions
Among eight tested adamantyl (alkyl, cycloal-
kyl) derivatives of aminopropanol-2 in vitro 
and in vivo experiments anti-influenza activity 
was found for the compounds 5, 30 and 33. 
CTI of the compounds 30 and 33 was equally 
high in vitro experiment on the MDCK cell 
culture, but these compounds showed different 
degree of protective effect in vivo experiment 
on the influenza pneumonia mice model, as 
well as different influence on hemagglutinin 
properties of the influenza virus. The com-
pounds 5 and 33 were more effective in the 
therapeutic scheme of the in vivo experiment, 
whereas the anti-influenza drugs showed equal 
effect in both variants of the experiment (the 
therapeutic and prophylactic schemes of their 
administration). We suggest that these results 
may be explained by different mechanisms of 
action of the tested compounds on the flu virus. 
The data obtained give ground to further 
research of the compounds 5, 30 and 33 for 
possible elaboration of new antimicrobial 
drugs on their basis.
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Антигрипозна дія адамантил (алкіл, 
циклоалкіл) похідних амінопропанолу-2 
в дослідах in vitro та in vivo
О. М. Волощук, Ю. В. Короткий, С. Л. Рибалко, 
Д. Б. Старосила, В. П. Широбоков
Мета. Визначити антигрипозну активність у 8 сполук 
адамантил (алкіл, циклоалкіл) похідних амінопропа-
нолу-2 в дослідах in vitro та in vivo. Методи. Оцінку 
противірусної дії сполук проводили in vitro за знижен-
ням інфекційного титру вірусу грипу на культурі клі-
тин, та in vivo на моделі грипозної пневмонії у мишей. 
Результати. В досліді in vitro 3 сполуки серед 8 до-
сліджених пригнічують репродукцію вірусу грипу 
штаму А/FM/1/47(H1N1) на 2 lg ID50 і більше в кон-
центраціях від < 0,39 мкг/мл (сполуки №№ 30 і 33) до 
1,56 мкг/мл (сполука № 5), їх хіміотерапевтичні індек-
си стосовно цього вірусу становлять 256 та 16, відпо-
відно. В досліді in vivo при профілактичній схемі до-
сліду сполуки №№ 5 і 30 мають індекс ефективності 
(ІЕ) 60 %, а при лікувальній схемі досліду ІЕ сполук 
№№ 5 та 33 більше ніж в два рази перевищує цей по-
казник у ремантадину і становить 100 %. Висновки. 
Високі хіміотерапевтичні індекси та здатність при-
гнічувати репродукцію вірусу грипу на 2 lg ID50 і 
більше дозволяє віднести сполуки №№ 30, 33 і 5 до 
таких, що проявляють протигрипозну активність. Це 
також підтверджено в досліді in vivo.
К л юч ов і  с л ов а: вірус грипу, адамантил (алкіл, 
циклоалкіл) похідні амінопропанолу-2, антивірусна дія.
Антигриппозное действие адамантил (алкил, 
циклоалкил) производных аминопропанола-2 
в экспериментах in vitro и in vivo
Е. М. Волощук, Ю. В. Короткий, С. Л. Рыбалко, 
Д. Б. Старосила, В. П. Широбоков
Цель. Определить антигриппозную активность у 8 со-
единений адамантил (алкил, циклоалкил) производных 
аминопропанола-2 в экспериментах in vitro и in vivo. 
Методы. Противовирусное действие исследуемых 
соединений определяли in vitro по снижению инфек-
ционного титра вируса гриппа в культуре клеток 
MDCK и in vivo на модели гриппозной пневмонии у 
мышей. Результаты. 3 соединения среди 8 исследо-
ванных подавляют репродукцию вируса гриппа штамм 
А/FM/1/47(H1N1) на 2 lg ID50 и больше в концентра-
циях от < 0,39 мкг/мл (соединения №№ 30 и 33) до 
1,56 мкг/мл (соединение № 5), их химиотерапевтиче-
ские индексы (ХТИ) в отношении этого вируса состав-
ляют 256 и 16, соответственно. В эксперименте in vivo 
при профилактической схеме опыта соединения №№ 
5 и 30 имеют индекс эффективности (ИЭ) 60 %. ИЭ 
соединений №№ 5 и 33 при лечебной схеме опыта 
больше чем в два раза превышает этот показатель у 
Ремантадина и составляет 100 %. Выводы. Высокие 
ХТИ и способность подавлять репродукцию вируса 
гриппа на 2 lg ID50 и более позволяют отнести соеди-
нения №№ 30, 33 и 5 к таким, что проявляют проти-
вогриппозную активность. Это также подтверждено в 
експриментах in vivo.
К л юч е в ы е  с л ов а: вирус гриппа, адамантил (ал-
кил, циклоалкил) производные аминопропанола-2, 
антивирусное действие.
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